Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of HSL during use of the preventative intervention (by culture) · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Viral load (shedding) in saliva · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in viral load (shedding) in saliva compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ aciclovir 200 mg 5 times/day · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention (by culture) ‐ aciclovir 400 mg twice daily · participants with recurrent herpes labialis
Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention ‐ aciclovir 800 mg twice daily · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention ‐ aciclovir 400 mg twice daily · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (low certainty).
1 finding from 1 review
Severity (aborted lesions) of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in severity (aborted lesions) of attack of recurrent herpes labialis… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) may leads to lower incidence of herpes labialis after use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
It is very uncertain whether topical aciclovir and 348U87 cream (short‐term) changes incidence of herpes labialis during use of the preventative… compared with placebo (very low certainty).
2 findings from 1 review
Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Severity of attack of recurrent herpes labialis during use of the preventative intervention (maximum lesion area) · participants with recurrent herpes labialis
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).
1 finding from 1 review